NCT06670872
A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia
StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
clinical efficacy at the end of treatment
Timeframe: up to the end of treatment, up to 4 weeks(estimation)
Secondary (3)
Incidence Rate of Adverse Event
The microbiological clearance rate
The all cause mortality rate
Arms and interventions
Eravacycline combination therapy group
Eravacycline is administered intravenously at a dosage of 1mg/kg, once every 12 hours. The duration of intravenous infusion is approximately 60 minutes.The combined drugs include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., used according to their instructions for use or clinical practice guidelines.
Drugs: Eravacycline combination therapy group
Sites
2 sites in 1 country